No quarterly revenue total was found in MBX Biosciences, Inc.'s SEC filings.
MBX Biosciences, Inc. (MBX) files with the SEC under industry code 2834, Pharmaceutical Preparations. Free cash flow was -$23.5 million. As of Jun 30, 2026 it held $418.6 million in cash and investments and $3.3 million in total debt.
Revenue
—
Net income
$-37.09M
-91.1% vs year-ago quarter
Operating cash flow
$-22.62M
-29.8% vs year-ago quarter
Free cash flow
$-23.52M
-29.7% vs year-ago quarter
EPS
$-0.78
-34.5% vs year-ago quarter
Dividend per share
None
Shares outstanding
48.16M
+43.4% vs year-ago quarter
Net cash
$415.24M
Q2 FY2026
Operating margin
—
Company profile
- Industry
- Pharmaceutical Preparations (SIC 2834)
- Listed as
- MBX (Nasdaq)
- Fiscal year ends
- December 31
- Incorporated in
- DE
- Headquarters
- Carmel, IN
- SEC filer status
- , Emerging growth company
- SEC CIK
- 1776111
Other Pharmaceutical Preparations companies
- ELI LILLY & Co LLY
- Johnson & Johnson JNJ
- AbbVie Inc. ABBV
- Merck & Co., Inc. MRK
- Novartis AG NVS
- Astrazeneca PLC AZN
- Abbott Laboratories ABT
- Novo Nordisk A S NVO
Key figures
Fiscal-year totals from the annual reports; switch to Annual for the full-year view. Balance sheet lines are as of each year end.
| Line | Q2 FY2026 Jun 30, 2026 |
Q1 FY2026 Mar 31, 2026 |
Q4 FY2025 Dec 31, 2025 |
Q3 FY2025 Sep 30, 2025 |
Q2 FY2025 Jun 30, 2025 |
|---|---|---|---|---|---|
| Operating income | -$40.9M | -$27.3M | -$25.8M | -$23.9M | -$21.8M |
| Net income | -$37.1M | -$23.5M | -$22.1M | -$21.6M | -$19.4M |
| Diluted EPS | -$0.78 | -$0.50 | -$0.49 | -$0.63 | -$0.58 |
| Operating cash flow | -$22.6M | -$20.2M | -$18.3M | -$21.5M | -$17.4M |
| Free cash flow | -$23.5M | -$20.6M | -$19.1M | -$21.9M | -$18.1M |
| Total assets | $435.9M | $452.7M | $385.1M | $400.1M | $231.5M |
| Total liabilities | $26.4M | $14.9M | $15.9M | $12.5M | $12.3M |
| Stockholders' equity | $409.5M | $437.8M | $369.2M | $387.5M | $219.2M |
| Cash and investments | $418.6M | $440.0M | $373.7M | $391.7M | $224.9M |
| Total debt | $3.3M | $555,000 | $596,000 | $623,000 | $650,000 |
Recent SEC filings
| Form | Description | Filed | Period |
|---|---|---|---|
| 8-K |
Current report
Officer or director change
|
Oct 22, 2026 | Oct 20, 2026 |
| 8-K |
Current report
Regulation FD disclosure, Other events
|
Aug 27, 2026 | Aug 27, 2026 |
| 10-Q | Quarterly report | Aug 6, 2026 | Jun 30, 2026 |
| 8-K |
Current report
Results of operations, Regulation FD disclosure, Other events
|
Aug 6, 2026 | Aug 6, 2026 |
| 8-K |
Current report
Officer or director change
|
Jul 13, 2026 | Jul 9, 2026 |
| 8-K |
Current report
Regulation FD disclosure, Other events
|
Jun 12, 2026 | Jun 12, 2026 |
All 232 MBX Biosciences, Inc. SEC filings
Source: SEC EDGAR filings. This is company-reported data, not investment advice.